Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors
Shots:
- Genentech to acquire Jecure, in all stock transaction for the portfolio of preclinical NLRP3 inhibitors
- The acquisition is focus to develop therapies using Jecure’s NLRP3 inhibitors for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis
- NLRP3 – Nucleotide-binding oligomerization (NOD)-like Receptor Family Pyrin Domain Containing Protein3, investigated for the treatment of autoimmune and inflammatory disorders
Click here to read full press release/ article | Ref: Jecure Therapeutics | Image: Xconomy